UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis

British journal of cancer, 2018-11, Vol.119 (10), p.1259-1266

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of metastatic estrogen receptor and progesterone receptor status on survival

Breast cancer research and treatment, 2005-03, Vol.90 (1), p.65-70

2005

Link zum Volltext

Verfügbarkeit prüfen

HER-2/neu expression in primary and metastatic breast cancer

Breast cancer research and treatment, 2009, Vol.113 (2), p.301-306

2009

Link zum Volltext

Verfügbarkeit prüfen

HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1

Cancer research (Chicago, Ill.), 2018-01, Vol.78 (2), p.422-435

2018

Link zum Volltext

Verfügbarkeit prüfen

Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2321-2327

2004

Link zum Volltext

Verfügbarkeit prüfen

MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients

Breast cancer research and treatment, 2020-06, Vol.181 (3), p.529-540

2020

Link zum Volltext

Verfügbarkeit prüfen

Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study

Cancer chemotherapy and pharmacology, 2018-07, Vol.82 (1), p.165-170

2018

Link zum Volltext

Verfügbarkeit prüfen

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

Breast cancer targets and therapy, 2017-01, Vol.9, p.515-520

2017

Link zum Volltext

Verfügbarkeit prüfen

HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling

Oncotarget, 2017-08, Vol.8 (35), p.58918-58933

2017

Link zum Volltext

Verfügbarkeit prüfen

Biomarker discordance: why it occurs and why it is important

Cancer biomarkers : section A of Disease markers, 2012-01, Vol.12 (6), p.219

2012

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Fulvestrant in Clinical Practice: Use of an Electronic Data Registry

Clinical breast cancer, 2007-04, Vol.7 (7), p.565-569

2007

Link zum Volltext

Verfügbarkeit prüfen

The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer

Breast cancer research and treatment, 1999-12, Vol.58 (3), p.205-211

1999

Link zum Volltext

Verfügbarkeit prüfen

Emerging Therapeutic Approaches to Overcome Breast Cancer Endocrine Resistance

Estrogen Receptor and Breast Cancer, 2019, p.379-403

2019

Link zum Volltext

Verfügbarkeit prüfen

c-myc,c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma

Cancer research (Baltimore), 1992-05, Vol.52 (9), p.2597-2602

1992

Link zum Volltext

Verfügbarkeit prüfen

Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis

Breast cancer research and treatment, 1995-09, Vol.35 (3), p.277-282

1995

Link zum Volltext

Verfügbarkeit prüfen

Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer : A comparative study

American journal of clinical oncology, 1996-12, Vol.19 (6), p.552-557

1996

Link zum Volltext

Verfügbarkeit prüfen

Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens

Breast cancer research and treatment, 1993, Vol.26 (3), p.217-224

1993

Link zum Volltext

Verfügbarkeit prüfen

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Breast cancer research and treatment, 2018-08, Vol.171 (1), p.11-20

2018

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Breast cancer research and treatment, 2018-05, Vol.169 (1), p.1-7

2018

Link zum Volltext

Verfügbarkeit prüfen

Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features

Clinical cancer research, 1996-11, Vol.2 (11), p.1873-1878

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Current Content Access

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(19)
Buchkapitel
(1)

Sprache

Englisch
(20)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis

Impact of metastatic estrogen receptor and progesterone receptor status on survival

HER-2/neu expression in primary and metastatic breast cancer

HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1

Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study

MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients

Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling

Biomarker discordance: why it occurs and why it is important

Evaluation of Fulvestrant in Clinical Practice: Use of an Electronic Data Registry

The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer

Emerging Therapeutic Approaches to Overcome Breast Cancer Endocrine Resistance

c-myc,c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma

Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis

Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer : A comparative study

Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features

Aktive Filter

Suchergebnisse filtern